Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Cara Therapeutics, Inc.

Cara Therapeutics is a biopharmaceutical company focused on developing treatments for pruritus (itching), particularly for patients with chronic kidney disease undergoing hemodialysis.

Cara Therapeutics

Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company is developing an oral formulation of difelikefalin, a selective, peripherally acting, non-scheduled kappa opioid receptor agonist, for the treatment of chronic pruritus associated with notalgia paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back for which there are no FDA-approved therapies. The Company is conducting a Phase 2/3 clinical program in NP with topline results of the dose-finding portion expected in the third quarter of 2024. Cara Therapeutics also developed an IV formulation of difelikefalin, which is approved in the United States, EU, and multiple other countries for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Devon Park BioVentures

Connecticut Innovations

Alta Partners

Ascent Biomedical Ventures

MVM Life Science Partners

Mitsubishi Corporation

Rho Capital Partners

Scottish Widows Investment Partnership

June 3rd is National Itch Day! At Cara Therapeutics, we understand that #pruritus is more than just an #itch for the millions of people who suffer from the burdensome condition. Chronic pruritus can be all-consuming and have a significant impact on overall well-being.

To learn how we’re working to transform the way pruritus is treated, visit www.CaraTherapeutics.com. #NationalItchDay

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023 
https://lnkd.in/eaUj8FW8

Cara Therapeutics Reports First Quarter 2024 Financial Results https://lnkd.in/ehp6ZXKw

Today we honor the women and men who lost their lives while serving our nation. We will always remember their sacrifices for our freedom.

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 https://lnkd.in/eGKrm2U8

Our Cara Culture Club recently sponsored a school supply drive for SPEF - Stamford Public Education Foundation and gathered donations for K.T. Murphy Elementary School. We wish all the students and teachers a healthy and productive school year! #Stamford #CaraCares

Metric
Company Name	Cara Therapeutics, Inc.
Symbol	CARA
MSH ID	COM:CARATHERAPEUTICS
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	55
Website	caratherapeutics.com
LinkedIn	cara-therapeutics
Founders

Metric
Market Cap	15.64M
Enterprise Value
Monthly Web Traffic	3.33K
Web Traffic Growth	1.80
Valuation
Raised Capital	40M

Metric
Revenue	20.97M
Revenue (LTM)
Revenue (NTM)
Gross Profit	14.54M
EBITDA	-121.24M
Operating Income	-121.50M
Net Income	-118.51M
EPS	-2.19
Diluted EPS	-2.19
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.74
Operating Profit Margin	-5.75
EBITDA Margin	-5.78
Net Profit Margin	-5.61
Return on Equity	-1.21
Return on Assets	-0.93
Return on Capital Employed	-1.20

COM:CARATHERAPEUTICS

Cara Therapeutics

Last Close

0.31

22/11 21:00

Market Cap

15.64M

Beta: -

Volume Today

508.47K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.27
P/B Ratio	0.36
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.54
EV Multiple	-0.13

Metric
Days Sales Outstanding	98.54
Days Payables Outstanding	378.37
Days Inventory Outstanding	231.16
Operating Cycle	294.11
Cash Conversion Cycle	243.48
Asset Turnover	0.19

Metric
Operating Cash Flow	-92.08M
Free Cash Flow	-94.45M
Cash Flow to Debt	-2.01
Operating Cash Flow/Sales	-4.39
Free Cash Flow Yield	-3.15

Metric
Cash & Equivalents	52.18M
Accounts Receivable	436K
Inventory	2.82M
Goodwill
Debt to Capitalization	0.77
Debt to Assets	0.06
Current Ratio	4.40
Quick Ratio	5.20

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.66
R&D to Revenue	5.00
SG&A to Revenue	1.30